Financials in USD. Standardized financial statements.
A compact view of how Aerpio Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $7.14M | $25.98M | $5.51M | $4.47M | $823,000 | $0 | $0 | $0 |
| Revenue Growth? | -72.5% | +371.7% | +23.1% | +443.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $35.02M | $20.02M | $14.44M | $8.32M | $0 | $0 |
| Gross Profit? | $0 | $0 | -$29.51M | -$15.54M | -$13.62M | -$8.32M | $0 | $0 |
| Gross Margin? | 0.0% | 0.0% | -535.7% | -347.4% | -1655.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $121.55M | $93.44M | $7.44M | $7.55M | $7.96M | $10.32M | $15.93M | $15.33M |
| Operating Income? | -$114.40M | -$67.46M | -$36.95M | -$23.82M | -$21.59M | -$17.99M | -$10.89M | -$15.46M |
| EBITDA? | -$114.40M | -$67.46M | -$36.05M | -$22.65M | -$20.47M | -$16.64M | -$9.54M | -$13.92M |
| Income Before Tax | -$20.60M | -$63.69M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$15.13M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$20.60M | -$63.69M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$15.13M |
| EPS? | $-0.33 | $-2.36 | $-1.08 | $-0.96 | $-1.35 | $-2.43 | $-3.59 | $-2.25 |
| Diluted EPS? | $-0.33 | $-2.36 | $-1.08 | $-0.96 | $-1.35 | $-2.43 | $-3.59 | $-2.25 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality